Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance-a controlled study

International Journal of Antimicrobial Agents

Volumn 30, Issue 3, 2007, Pages 264-269

  Schentag, Jerome J ^a,b   Klugman, Keith P ^c   Yu, Victor L ^d   Adelman, Martin H ^a,b   Wilton, Gregory J ^a,b   Chiou, Christine C ^e   Patel, Manish ^f   Lavin, Bruce ^f   Paladino, Joseph A ^a,b  

^a CPL Associates LLC   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f SANOFI   (France)

Author keywords

CAP; Macrolides; Pharmacodynamics; Streptococcus pneumoniae; Treatment failures

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZITHROMYCIN; BACTEREMIA; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; RETROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

EID: 34547416996     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.04.013     Document Type: Article

References (22)

1. Fogarty C., Goldschmidt R., and Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 31 (2000) 613-615
2. Van Kerkhoven D., Peetermans W.E., Verbist L., and Verhaegen J. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother 51 (2003) 691-696
3. Waterer G.W., Wunderink R.G., and Jones C.B. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 118 (2000) 1839-1840
4. Kelley M.A., Weber D.J., Gilligan P., and Cohen M.S. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 31 (2000) 1008-1011
5. Lonks J.R., Garau J., Gomez L., et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 35 (2002) 556-564
6. Daneman N., McGeer A., Green K., and Low D.E. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 43 (2006) 432-438
7. Grant G., Barrett N., Bennett N., et al. Macrolide resistance in breakthrough pneumococcal bacteremia. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (2006), 27-30 September, San Francisco, CA 369-370 (Abstract L-1077)
8. Musher D.M., Dowell M.E., Shortridge V.D., et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 346 (2002) 630-631
9. Metlay J., Fishman N.O., Joffe M., Kallan M.J., Chittams J.L., and Edelstein P.H. Macrolide resistance in adults with bacteremic pneumococcal pneumonia. Emerg Infect Dis 8 (2006) 1223-1230
10. Jacobs M.R. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin Infect Dis 35 (2002) 565-569
11. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption?. J Chemother 11 Suppl. 1 (1999) 35-43
12. Zhanel G.G., DeCorby M., Noreddin A., et al. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J Antimicrob Chemother 52 (2003) 83-88
13. Yu V.L., Chiou C.C., Feldman C., et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 37 (2003) 230-237
14. Amsden G.W., Ballow C.H., and Schentag J.J. Population pharmacokinetic methods to optimise antibiotic effects. Drug Investig 5 (1993) 256-268
15. Iannini P, Paladino JA, Adelman MH, Forrest A, Schentag JJ. Macrolide and beta lactam failure is an identifiable clinical event. In: 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA); 30 September-3 October 2004; Boston, MA. Late Breaker Symposium LB-6.
16. Rodvold K.A., Danziger L.H., and Gotfried M.H. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 47 (2003) 2450-2457
17. Patel K.B., Xuan D., Tessier P.R., Russomanno J.H., Quintiliani R., and Nightingale C.H. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 40 (1996) 2375-2379
18. Gotfried M.H., Danziger L.H., and Rodvold K.A. Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects. J Antimicrob Chemother 52 (2003) 450-456
19. Capitano B., Mattoes H.M., Shore E., et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 125 (2004) 965-973
20. Andes D., Anon, Jacobs M.R., and Craig W.A. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med 24 (2004) 477-502
21. Moellering Jr. R.C., Craig W., Edmond M., et al. Clinical and public health implications of macrolide-resistant Streptococcus pneumoniae. J Chemother 14 Suppl. 3 (2002) 42-56
22. Tran J.Q., Ballow C.H., Forrest A., et al. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. J Antimicrob Chemother 45 (2000) 9-17